Abiopharma

PENNANTPARK FLOATING RATE CAPITAL LTD. (PFLT) Reports the reporting period Financial Results PENNANTPARK FLOATING RATE CAPITAL LTD. (PFLT) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: Not disclosed
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 31427
  • AVAILABLE INFORMATION The Company makes available on its website its Quarterly Report on Form 10
  • Q filed with the SEC, and stockholders may find such report on its website at www.pennantpark.com. PENNANTPARK FLOATING RATE CAPITAL LTD. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES(in thousands, except per share data) March 31, 2026 September 30, 2025 Assets(unaudited) Investments at fair value Non
  • affiliated investments (amortized cost— $2,151,925 and $2,458,018, respectively)$2,189,011 $2,491,360 Controlled, affiliated investments (amortized cost— $494,500 and $361,375, respectively) 391,270 281,968 Total investments (amortized cost— $2,646,425 and $2,819,393, respectively) 2,580,281 2,773,328 Cash equivalents (cost— $31,427 and $40,729, respectively) 31,427 40,729 Cash (cost— $90,446 and $81,955, respectively) 90,444 81,959 Interest receivable 12,611 13,832 Distributions receivable 900 — Receivable for investments sold 30,052 1,369 Due from affiliate 136 321 Prepaid expenses and other assets 2,085 2,143 Total assets 2,747,936 2,913,681 Liabilities Credit Facility payable, at fair value (cost— $328,355 and $683,855, respectively) 328,333 683,837 2026 Notes payable, net (par—$185,000) (unamortized deferred financing costs of $2 and $391, respectively) 184,998 184,609 2029 Notes payable, net (par—$200,000 and $0) (unamortized deferred financing costs of $4,132 and $0, respectively) 195,868 — 2036 Asset